Dr. Raimondo’s research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her research primarily focuses on the development of novel lipid nanoparticles (LNPs) for RNA-based therapies, and her work has contributed to the development of adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By using engineering approaches to optimize LNP formulation as well as modulating RNA constructs (sequence and chemical modifications), Dr. Raimondo seeks to both better understand how RNA-LNPs modulate immunity and to use this understanding for the development of new therapies.